Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline

AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab for cancer and benralizumab for asthma are among important milestones ahead.